

Prior Authorization must be requested and approved for the drug AND for administration in an outpatient hospital setting (POS code 19 or 22). The preferred Site of Care for all drugs listed are office (11) and home infusion (12), unless otherwise indicated below.

| DRUG TRADE NAME | HCPCS | TARGET INDICATION | BIOSIMILAR PRODUCT? | EFFECTIVE DATE |
|-----------------|-------------|-------------------|---------------------|----------------|
| Actemra | J3262 | All | N | 4/6/2020 |
| Actimmune | J9216 | All | N | 7/1/2020 |
| Adakveo | J0791 | All | N | 5/21/2020 |
| Aldurazyme | J1931 | All | N | 4/6/2020 |
| Aralast NP | J0256 | All | N | 4/6/2020 |
| Arcalyst | J2793 | All | N | 7/1/2020 |
| Apretude | J0739 | All | N | 10/1/2022 |
| Asceniv | J1554 | All | N | 4/23/2021 |
| Avsola | Q5121 | All | Y - to Remicade | 7/1/2020 |
| Benlysta | J0490 | All | N | 4/6/2020 |
| Berinert | J0597 | All | N | 4/6/2020 |
| Bivigam | J1556 | All | N | 4/6/2020 |
| Cerezyme | J1786 | All | N | 4/6/2020 |
| Cinqair | J2786 | All | N | 4/6/2020 |
| Cinryze | J0598 | All | N | 4/6/2020 |
| Crysvita | J0584 | All | N | 4/6/2020 |
| Cutaquig | J1551 | All | N | 4/6/2020 |
| Cuvitru | J1555 | All | N | 4/6/2020 |
| Elaprase | J1743 | All | N | 4/6/2020 |
| Elelyso | J3060 | All | N | 4/6/2020 |
| Empaveli | C9399 (NOC) | All | N | 11/15/2021 |
| Entyvio | J3380 | All | N | 4/1/2019 |
| Evenity | J3111 | All | N | 5/23/2021 |
| Evkeeza | J1305 | All | N | 4/23/2021 |
| Exondys 51 | J1428 | All | N | 4/6/2020 |
| Fabrazyme | J0180 | All | N | 4/6/2020 |
| Fasenra | J0517 | All | N | 4/6/2020 |
| Fensolvi | J1951 | All | N | 7/1/2020 |
| Flebogamma | J1572 | All | N | 4/6/2020 |
| Gammagard | J1569 | All | N | 4/6/2020 |
| Gammagard S/D | J1566 | All | N | 7/1/2020 |

| DRUG TRADE NAME | HCPCS | TARGET INDICATION | BIOSIMILAR PRODUCT? | EFFECTIVE DATE |
|-----------------|-------|-------------------|---------------------|----------------|
| Gammaked | J1561 | All | N | 4/6/2020 |
| Gammalex | J1557 | All | N | 4/6/2020 |
| Gamunex-C | J1561 | All | N | 4/6/2020 |
| Givlaari | J0223 | All | N | 7/1/2020 |
| Glassia | J0257 | All | N | 4/6/2020 |
| Hizentra | J1559 | All | N | 4/6/2020 |
| Hyqvia | J1575 | All | N | 4/6/2020 |
| Ilaris | J0638 | All | N | 4/6/2020 |
| Inflectra | Q5103 | All | Y - to Remicade | 4/1/2019 |
| Kanuma | J2840 | All | N | 4/6/2020 |
| Krystexxa | J2507 | All | N | 4/6/2020 |
| Lemtrada* | J0202 | All | N | 4/1/2019 |
| Leqvio | J1306 | All | N | 8/24/2022 |
| Lumizyme | J0221 | All | N | 4/6/2020 |
| Mepsevii | J3397 | All | N | 4/6/2020 |
| Naglazyme | J1458 | All | N | 4/6/2020 |
| Nucala | J2182 | All | N | 4/6/2020 |
| Nulojix | J0485 | All | N | 4/6/2020 |
| Ocrevus* | J2350 | All | N | 4/1/2019 |
| Octagam | J1568 | All | N | 4/6/2020 |
| Orencia | J0129 | All | N | 4/6/2020 |
| Oxlumo | J0224 | All | N | 4/23/2021 |
| Panzyga | J1599 | All | N | 4/6/2020 |
| Phesgo | J9316 | All | N | 7/1/2020 |
| Privigen | J1459 | All | N | 4/6/2020 |
| Prolastin-C | J0256 | All | N | 4/6/2020 |
| Prolia/Xgeva | J0897 | Non-Oncology | N | 4/1/2019 |
| Reblozyl | J0896 | All | N | 7/1/2020 |
| Remicade | J1745 | All | N | 4/1/2019 |
| Remodulin | J3285 | All | N | 4/6/2020 |
| Renflexis | Q5104 | All | Y - to Remicade | 4/1/2019 |
| Riabni* | Q5123 | Non-Oncology | Y – to Rituxan | 4/23/2021 |
| Rituxan* | J9312 | Non-Oncology | N | 4/1/2019 |
| Ruconest | J0596 | All | N | 4/6/2020 |
| Ruxience* | Q5119 | Non-Oncology | Y – to Rituxan | 10/22/2019 |
| Ryplazim | J2998 | All | N | 5/1/2022 |
| Saphnelo | J0491 | All | N | 2/8/2022 |
| Simponi Aria | J1602 | All | N | 4/1/2019 |

| DRUG TRADE NAME | HCPCS | TARGET INDICATION | BIOSIMILAR PRODUCT? | EFFECTIVE DATE |
|-----------------|-------|--|---------------------|----------------|
| Stelara (IV) | J3358 | Crohn's Disease/ Ulcerative Colitis | N | 4/1/2019 |
| Strensiq | J3490 | All | N | 4/6/2020 |
| Tezspire | J2356 | All | N | 8/24/2022 |
| Truxima* | Q5115 | Non-Oncology | Y – to Rituxan | 10/22/2019 |
| Tysabri* | J2323 | All | N | 4/1/2019 |
| Ultomiris | J1303 | All | N | 7/1/2020 |
| Uplizna | J1823 | All | N | 7/1/2020 |
| Vimizim | J1322 | All | N | 4/6/2020 |
| Vpriv | J3385 | All | N | 4/6/2020 |
| Vyepti | J3032 | All | N | 7/1/2020 |
| Vyvgart | J9332 | All | N | 8/24/2022 |
| Xembify | J1558 | All | N | 4/6/2020 |
| Xolair | J2357 | All | N | 4/6/2020 |
| Zemaira | J0256 | All | N | 4/6/2020 |

*Drug is not recommended for home infusion. Office or infusion suite (clinic, home, or pharmacy based) are the preferred settings.